Coronary disease & ACSRandomised controlled trial
SGLT2 Inhibitor on Infarct Size and Left Ventricular (LV) Remodeling by CMR in Patients With Acute Myocardial Infarction (AMI)
- Randomised controlled trial
- prospective
- open-label
Authors' conclusion
Among patients with AMI undergoing PCI who were at high risk for heart failure, SGLT2 inhibitor use did not reduce infarct size or facilitate reverse LV remodeling at 6 months as assessed by CMR.
Study context
- Population
- Patients ≥18 years with AMI at high risk for HF after successful percutaneous coronary intervention (PCI)169 (84.0%) with 6-month CMR
- Participants
- 200 patients
- Comparison
- Empagliflozin 10 mg once daily vs no SGLT2 inhibitor
- SGLT2 inhibitorn = 100
- Controln = 100reference
- Primary endpoint
- Infarct size (% LV mass) by CMR; coprimary: ΔLV end-systolic volume by CMR between baseline and 6 months
- Follow-up
- 6 months
Primary result
As reported in the abstract
| Group | Infarct size (% LV mass) | ΔLV end-systolic volume |
|---|---|---|
| SGLT2 inhibitor | 12.5% [8.5%-20.9%] | −3.3% [−19.7% to 13.6%] |
| Control | 12.9% [5.0%-20.7%] | −6.8% [−23.4% to 10.6%] |
- SGLT2 inhibitor vs Control: P = 0.92 — infarct size
- SGLT2 inhibitor vs Control: P = 0.40 — ΔLV end-systolic volume (coprimary)
Original publication
SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI. JACC Cardiovasc Interv. Published 27 July 2026. doi:10.1016/j.jcin.2026.04.017
Summarised from the published abstract; every number is checked against it